NCT05986136CompletedPhase 2/3
Dapagliflozin in Patients With Ulcerative Colitis
Clinical Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Ulcerative Colitis
Source: ClinicalTrials.gov · Last updated 21 Sept 2026
Brief summary (registry, in English)
The inflammatory bowel diseases (IBD) are described as complex, recurrent inflammatory conditions which are manifested as Crohn's disease (CD) and ulcerative colitis (UC). The common symptoms of IBD include debilitating/severe diarrhea, abdominal pain, weight loss, and chronic fatigue; events that may culminate in life-threatening complications. The pathogenesis of IBD has been characterized as complex/multi-factorial that includes disruption of intestinal epithelial barrier with consequent translocation of commensal microbial products as the prime event that instigates severe immune responses and intestinal inflammation.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 2 Aug 2023
- Start date
- 20 Aug 2023
- Primary completion date
- 20 Aug 2026
- Lead sponsor
- Mostafa Bahaa
- Diseases
- Ulcerative colitis
- NCT number
- NCT05986136
What you commit to
- Study type: Interventional · Phase 2/3
- Participants enrolled: 60
- From 20 Aug 2023 to the primary completion date, 20 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients taking rectal or systemic steroids
- Patients taking immunosuppressives or biological therapies
- Addiction to alcohol and / or drugs
Other illness
- Colorectal cancer patients
- Known allergy to the dapagliflozin
Other
- Breast feeding
- Significant liver and kidney function abnormalities
- Patients with severe UC
Who the study is looking for
- Age ≥ 18 years
- Both male and female will be
- Mild and moderate UC patients diagnosed and confirmed by endoscope
Age in the registry: 18 months to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculty of Medicine, Mansoura University Coordinator of this site? Confirm its status | Al Mansurah | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.